Project Details
Description
A Randomized, Double-blind, Multi-Center Phase 3 of ADI-PEG 20 plus best supportive Care (BSC) vs Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed Prior Systemic Therapy
Status | Finished |
---|---|
Effective start/end date | 9/27/11 → 12/30/15 |
Funding
- Polaris Pharmaceuticals, Inc.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.